Advertisement

Medical Oncology

, 31:205 | Cite as

Elevated level of microRNA-21 in the serum of patients with colorectal cancer

  • Gholam Basati
  • Amirnader Emami RazaviEmail author
  • Soheila Abdi
  • Asad Mirzaei
Original Paper

Abstract

In patients with colorectal cancer, circulating micro RNA-21 (miR-21) is overexpressed and may act as a potential diagnostic and prognostic biomarker. In the present study, serum miR-21 level was determined in patients with colorectal cancer and control subjects in an attempt to explore its potential clinical diagnostic and prognostic value. Serum levels of miR–21 were measured in 40 patients with colorectal adenocarcinoma and 40 control subjects using a quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) assay. Serum miR-21 levels were compared in the colorectal cancer patients and control subjects. Furthermore, the association between serum miR-21 level and the clinical stages of tumors was also examined in the patients. Serum miR-21 level was significantly elevated in colorectal adenocarcinoma patients relative to control subjects (P = 0.0001), and it was revealed as a potential diagnostic biomarker for differentiating the patients from control subjects. Increased levels of serum miR-21 were associated with clinical stages of tumors in the patients (P = 0.01). These results indicated that serum miR-21 levels could serve as a reliable diagnostic and prognostic biomarker for colorectal adenocarcinoma.

Keywords

Serum miR-21 Colorectal adenocarcinoma Clinical staging qRT-PCR 

Notes

Acknowledgments

This study was supported by the research Grant, EC/92/H/136, from Ilam University of Medical Sciences.

Conflict of interest

The authors declare that there are no financial conflicts of interest.

References

  1. 1.
    Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92–105.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Bushati N, Cohen SM. MicroRNA functions. Annu Rev Cell Dev Biol. 2007;23:175–205.PubMedCrossRefGoogle Scholar
  4. 4.
    Schoof CRG, Da Silva Botelho EL, Izzotti A, Dos Reis Vasques L. MicroRNAs in cancer treatment and prognosis. Am J Cancer Res. 2012;2(4):414.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Liang Y, Ridzon D, Wong L, Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genom. 2007;8(1):166.CrossRefGoogle Scholar
  6. 6.
    Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular microRNA: a new source of biomarkers. Mutat Res/Fundam Mol Mech Mutagen. 2011;717(1):85–90.CrossRefGoogle Scholar
  8. 8.
    Luo X, Burwinkel B, Tao S, Brenner H. MicroRNA signatures: novel biomarker for colorectal cancer? Cancer Epidemiol Biomark Prev. 2011;20(7):1272–86.CrossRefGoogle Scholar
  9. 9.
    Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg. 2012;256(3):544–51.PubMedCrossRefGoogle Scholar
  10. 10.
    Volinia S, Calin GA, Liu C-G, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006;103(7):2257–61.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR, et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomark Prev. 2010;19(7):1766–74.CrossRefGoogle Scholar
  12. 12.
    Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA. 2008;299(4):425–36.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Kulda V, Pesta M, Topolcan O, Liska V, Treska V, Sutnar A, et al. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases. Cancer Genet Cytogenet. 2010;200(2):154–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology. 2011;79(3–4):313–20.Google Scholar
  15. 15.
    Nielsen BS, Jørgensen S, Fog JU, Søkilde R, Christensen IJ, Hansen U, et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients. Clin Exp Metastasis. 2011;28(1):27–38.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔC Tmethod. Methods. 2001;25(4):402–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 2012;138(10):1659–66.PubMedCrossRefGoogle Scholar
  18. 18.
    Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105(12):849–59.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Li B-S, Zhao Y-L, Guo G, Li W, Zhu E-D, Luo X, et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One. 2012;7(7):e41629Google Scholar
  20. 20.
    Liu R, Chen X, Du Y, Yao W, Shen L, Wang C, et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem. 2012;58(3):610–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 2011;57(1):84–91.PubMedCrossRefGoogle Scholar
  22. 22.
    Agaoglu FY, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biol. 2011;32(3):583–8.CrossRefGoogle Scholar
  23. 23.
    Zen K, Zhang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev. 2012;32(2):326–48.PubMedCrossRefGoogle Scholar
  24. 24.
    Bullock M, Pickard KM, Nielsen B, Sayan A, Jenei V, Mellone M, et al. Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis. 2013;4(6):e684.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Gholam Basati
    • 1
  • Amirnader Emami Razavi
    • 2
    Email author
  • Soheila Abdi
    • 3
  • Asad Mirzaei
    • 4
  1. 1.Department of Clinical Biochemistry, Faculty of Allied Medical SciencesIlam University of Medical SciencesIlamIran
  2. 2.Iran National Tumor Bank, Cancer InstituteTehran University of Medical SciencesTehranIran
  3. 3.Department of Physics, Safadasht BranchIslamic Azad UniversityTehranIran
  4. 4.Department of Parasitology, Faculty of MedicineIlam University of Medical ScienceIlamIran

Personalised recommendations